Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Ethinyl Estradiol--indications”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

12 recordsLinked to original sources
PubMed1981

Hypersecretion of an abnormal form of follicle-stimulating hormone associated with suppressed luteinizing hormone secretion in a woman with a pituitary adenoma.

Pituitary tumors producing FSH have hitherto been reported only in males, all of whom have had normal or raised LH levels in serum. This report describes a female with a pituitary adenoma associated with supranormal serum levels of FSH. The FSH was also qualitatively abnormal when compared with FSH in the serum of other postmenopausal women, had a lower apparent molecular weight on gel chromatography, and was less negatively charged, as shown by electrophoresis. The results of LRH tests and suppression tests with ethinyl estradiol indicated autonomy of the FSH-producing adenoma. The FSH level increased concomitant with tumor enlargement and decreased after surgical removal of the pituitary adenoma or pituitary irradiation. The serum level of the glycoprotein alpha-subunit was raised about 100-fold. Any free FSH beta-subunits were not detectable in serum. The abnormal FSH had antigenic sites in common with both the alpha- and beta-subunits of FSH. The LH level was extremely low, and there was no response to LRH tests or ethinyl estradiol treatment. After gel chromatography, a small amount of LH, corresponding to 1/50th of the average for the patient's age, was detected at the position for normal LH. There was no GH response to insulin-induced hypoglycemia, while the cortisol increase was normal. Thyroid and adrenal functions were normal. The PRL level was within the normal range and increased slightly after estrogen treatment.

Adenoma↗
PubMed1978

Experience with a new low dose oral contraceptive: norgestimate & ethinyl estradiol.

Experience with cyclic administration of 0.125 mg of norgestimate plus 0.035 mg of ethinyl estradiol indicates that this new combined oral contraceptive is clinically effective and well tolerated. There were no unintended pregnancies in 3,026 cycles of use among 161 women. Patient acceptability of a relatively high cycle incidence of spotting (16.7%) was remarkable; only five patients withdrew from the study because of this irregularity. Breakthrough bleeding was infrequent (0.9% of total cycles). No other side effects were reported and amenorrheic cycles were not observed. In particular there were no complaints of gastrointestinal disturbance. Weight remained unusually stable. Laboratory findings remained within normal limits over 6 months of drug use. However, serum cholesterol and serum glutamic pyruvic transaminase levels declined and protein bound iodine increased significantly from pre-treatment levels.

Adult↗
PubMed1990

Dissolution testing of norethindrone:ethinyl estradiol, norethindrone:mestranol, and norethindrone acetate:ethinyl estradiol combination tablets.

Dissolution of oral contraceptive combination products from six manufacturing firms was studied utilizing the rotating basket method at 100 rpm in 600 mL of 0.1 M HCl and 0.02% sodium lauryl sulfate (SLS). Most of the combination products of norethindrone (NE):ethinyl estradiol (EE) dissolved satisfactorily in water using the paddle method which was first proposed by U.S.P., whereas three of 18 tested products showed better dissolution in acidic aqueous medium containing SLS. Acidic medium with surfactant was also found to be suitable for combination products of norethindrone (NE):mestranol (ME) and norethindrone acetate (NEAc):ethinyl estradiol (EE). A modified U.S.P. assay procedure, a reversed-phase high-performance liquid chromatographic (HPLC) method with a mobile phase of acetonitrile and phosphate buffer, was used to analyze NE and EE concurrently. The NEAc and ME were analyzed separately in these combination products. The NEAc was found to hydrolyze to some extent (approximately 20% in 8 h) in acidic dissolution medium at room temperature, but less so at 4 degrees C. The NE was identified as the sole degradation product of NEAc hydrolysis and was also measured to account for the total amount of NEAc dissolved. A simple dissoluting testing method which utilizes a single dissolution medium was applicable for all oral contraceptive combination tablets surveyed.

1-Propanol↗
PubMed1994

Modification of the U.S.P. dissolution method for the analysis of norethindrone and ethinyl estradiol tablets.

A modification of the U.S.P. dissolution method for the quantitation of norethindrone and ethinyl estradiol tablets is proposed. This modification consists of the use of distilled water as the dissolution medium instead of 0.1 N hydrochloric acid (HCl) and/or neutralization of 0.1 N HCl with sodium carbonate prior to analysis. Statistical analysis of the results indicate that there are no significant differences between the dissolution in 0.1 N HCl and the dissolution in distilled water (p < 0.05) for norethindrone and ethinyl estradiol.

Chromatography, High Pressure Liquid↗
PubMed1987

Medroxyprogesterone acetate- and ethinylestradiol-induced changes in biliary bile acids of the rat studied by high-performance liquid chromatography.

The effects of subcutaneous administration (5 mg/kg per day) for seven days of medroxyprogesterone acetate (MPA) or 17 alpha-ethinylestradiol (EE) on bile flow, total bile acid output and individual biliary acids have been studied in adult male Wistar rats. Biliary bile acid composition was quantitated by a simple isocratic high-performance liquid chromatographic technique using a C18 reversed-phase radial compression column and refractive index detection. This method revealed that muricholic acids, analysed as taurine and glycine conjugates, constituted a higher proportion of biliary bile acids in the rat than previously observed with gas chromatographic techniques. Marked cholestasis was produced by EE while MPA had little effect on bile flow or total bile acid output. Despite this, both steroids significantly increased the proportion of taurine-conjugated muricholic acids relative to taurocholic acid, although the estrogen had the more pronounced effect. Further study of the hepatobiliary consequences of high doses of MPA would seem warranted in view of the important use of this progestogen for cancer therapy.

Animals↗
PubMed2001

The C terminus of the human nicotinic alpha4beta2 receptor forms a binding site required for potentiation by an estrogenic steroid.

In addition to actions mediated by changes in gene expression, steroids can directly modulate several transmitter-gated and voltage-gated ion channels. Despite numerous studies showing that steroids enhance or reduce ion channel activity, the site(s) that mediates steroid recognition is not known. To identify the regions in which steroids bind and affect ion channel activity, we have taken advantage of the observation that human alpha4beta2 neuronal nicotinic receptors are potentiated by an estrogen steroid, 17beta-estradiol, whereas a rat alpha4beta2 receptor is not. Mutations indicate that a sequence (AGMI) at the end of the C terminus of the human alpha4 subunit forms a binding site required for 17beta-estradiol potentiation. In contrast, ethynyl beta-estradiol (an oral contraceptive) potentiates both human and rat alpha4beta2 receptors. A single tryptophan in the C terminus of both the rat and the human alpha4 subunit is sufficient for potentiation by ethynyl beta-estradiol, probably through a pi-pi interaction. Mutation of this tryptophan eliminates the ability of ethynyl beta-estradiol to potentiate rat receptors. However, in human receptors it was necessary to mutate both the AGMI sequence and the tryptophan to eliminate potentiation by ethynyl beta-estradiol. The findings that beta-estradiol requires the AGMI sequence but that a single C-terminal tryptophan is sufficient for potentiation by ethynyl beta-estradiol indicate that the C terminus forms a binding site for these steroids. The binding site(s) for block appears to differ from those involved in potentiation because the C-terminal sequence does not affect block by steroids such as progesterone, and progesterone does not competitively inhibit potentiation.

Acetylcholine↗